A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Description

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

Conditions

Advanced Solid Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Condition
Advanced Solid Tumors
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Local Institution - 0007, Los Angeles, California, United States, 90033

Grand Rapids

START Midwest, Grand Rapids, Michigan, United States, 49546

Hackensack

Local Institution - 0004, Hackensack, New Jersey, United States, 07601

Pittsburgh

Local Institution - 0006, Pittsburgh, Pennsylvania, United States, 15232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
  • * CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:.
  • * NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:.
  • * History of anaphylactic reactions to irinotecan and/or bevacizumab.
  • * Previously received therapy targeting CEACAM5.
  • * Grade ≥ 3 ILD/pneumonitis.
  • * Other protocol-defined Inclusion/Exclusion criteria apply.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bristol-Myers Squibb,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2029-12-09